Ensartinib plus chemo before surgery for ALK+ lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether taking the targeted therapy Ensartinib (which blocks ALK) along with standard chemotherapy before surgery can help shrink ALK-positive lung cancer and improve outcomes. It is for people who have not yet had treatment and whose cancer is at a stage that can be removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have a type of lung cancer called adenocarcinoma that has an ALK gene change (fusion).
- Your cancer is at stage II, IIIA, or IIIB (N2), and your doctor says it can be surgically removed.
- You haven't had any other cancer treatment for this cancer before.
- You are in generally good health (able to do daily activities without help) and have normal organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug ensartinib to shrink lung cancer before surgery. It is for people with ALK-positive lung cancer that can be surgically removed.
This trial tests a pill called ensartinib, given before surgery to people with ALK-positive lung cancer. The goal is to see if it helps shrink the tumor and improve the chance of successful surgery.
This trial compares two treatments after lung cancer surgery: a new targeted drug (ensartinib) versus standard chemotherapy. The goal is to see if the targeted drug helps prevent the cancer from coming back.
This trial tests whether taking ensartinib after surgery can lower the chance of lung cancer coming back in people whose tumors have a specific genetic change called ALK. The study uses a blood test called MRD to guide treatment.
This trial tests whether taking a pill called ensartinib after surgery can help prevent early stage lung cancer from coming back. It is for people whose tumors have a specific gene change called ALK and who have high-risk features.
This study tests the drug ensartinib, given before surgery, for people with ALK-positive lung cancer. Taking ensartinib first might shrink the tumor and make surgery more effective.
Hear when a new NSCLC (Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.